EPS for Calian Group Ltd. (CGY) Expected At $0.49; Last Week Immune Design Corp. (IMDZ) Analysts

January 16, 2018 - By Stephen Andrade

Among 5 analysts covering Immune Design (NASDAQ:IMDZ), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Immune Design had 10 analyst reports since August 18, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Thursday, October 5 report. The stock has “Outperform” rating by Leerink Swann on Tuesday, August 18. The rating was maintained by Wells Fargo with “Market Perform” on Wednesday, October 18. The stock of Immune Design Corp. (NASDAQ:IMDZ) earned “Buy” rating by Cowen & Co on Tuesday, June 6. The firm earned “Buy” rating on Wednesday, September 9 by Jefferies. Jefferies maintained the shares of IMDZ in report on Monday, September 4 with “Buy” rating. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by Jefferies given on Wednesday, August 10. See Immune Design Corp. (NASDAQ:IMDZ) latest ratings:

18/10/2017 Broker: Wells Fargo Rating: Market Perform Old Target: $29 New Target: $10 Maintain
05/10/2017 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $20 Initiates Coverage On
04/09/2017 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain

Analysts expect Calian Group Ltd. (TSE:CGY) to report $0.49 EPS on February, 7.They anticipate $0.04 EPS change or 8.89% from last quarter’s $0.45 EPS. T_CGY’s profit would be $3.75 million giving it 16.36 P/E if the $0.49 EPS is correct. After having $0.56 EPS previously, Calian Group Ltd.’s analysts see -12.50% EPS growth. The stock decreased 1.05% or $0.34 during the last trading session, reaching $32.07. About 5,648 shares traded. Calian Group Ltd. (TSE:CGY) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Calian Group Ltd. engages in the systems engineering, manufacturing, training, information technology, and health care solutions to industries and government in Canada, the United States, and Europe. The company has market cap of $245.52 million. The company??s Systems Engineering division plans, designs, and implements solutions in satellite communications, defense/security, and high-end telecommunications sectors. It has a 15.96 P/E ratio. It offers radio frequency earth stations, gateway systems, capacity planning and management systems, and broadcast systems for communications and control of spacecraft for commercial and government applications.

Since August 1, 2017, it had 2 buys, and 6 sales for $21.80 million activity. $8,282 worth of stock was sold by ter Meulen Jan Henrik on Thursday, January 4. Svennilson Peter bought $10.99 million worth of stock. Yurasov Sergey had sold 675 shares worth $2,816 on Thursday, January 4. The insider Gombotz Wayne sold 10,000 shares worth $114,336. $13,885 worth of Immune Design Corp. (NASDAQ:IMDZ) was sold by Brady Stephen R on Thursday, January 4. Another trade for 2.68 million shares valued at $10.99M was bought by COLUMN GROUP L P. 7,970 shares were sold by Paya Carlos V, worth $33,247.

Investors sentiment decreased to 1.27 in 2017 Q3. Its down 1.17, from 2.44 in 2017Q2. It dived, as 5 investors sold Immune Design Corp. shares while 21 reduced holdings. 13 funds opened positions while 20 raised stakes. 11.88 million shares or 8.39% more from 10.96 million shares in 2017Q2 were reported. Dimensional Fund Advisors Lp has invested 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Panagora Asset holds 0.01% or 198,926 shares in its portfolio. Zacks Inv Mgmt holds 117,545 shares or 0.03% of its portfolio. Morgan Stanley reported 0% in Immune Design Corp. (NASDAQ:IMDZ). Blackrock Inc reported 1.04 million shares. Nationwide Fund Advisors holds 0.01% or 133,509 shares in its portfolio. Schwab Charles Invest holds 34,143 shares. Tower Capital Lc (Trc) has 0% invested in Immune Design Corp. (NASDAQ:IMDZ) for 2,225 shares. Acadian Asset Mgmt Limited Liability Company has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). 20,100 were reported by State Common Retirement Fund. Barclays Public Limited Com holds 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ) for 12,296 shares. Victory Management Inc holds 2.06M shares or 0.05% of its portfolio. Manufacturers Life Insur Com The reported 14,822 shares or 0% of all its holdings. 123,522 were accumulated by Geode Mngmt Llc. Eam Invsts Ltd Liability Corp owns 37,355 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: